in vitro fertilization

Size: px
Start display at page:

Download "in vitro fertilization"

Transcription

1 FERTILITY AND STERILITY VOL 69, NO. 6, JUNE 1998 Copyright (#1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Elevated levels of basal estradiol-17,6 predict poor response in patients with normal basal levels of folliclestimulating hormone undergoing in vitro fertilization Johannes L. H. Evers, M.D., Peronneke Slaats, M.S., Jolande A. Land, M.D., John C. M. Dumoulin, Ph.D., and Gerard A. J. Dunselman, M.D. Division of Reproductive Endocrinology and Fertility, Department of Obstetrics and Gynecology, Academisch Ziekenhuis Maastricht and The University of Maastricht, Maastricht, The Netherlands Objective: To evaluate whether the predictive ability of a normal FSH level on cycle day 3 can be enhanced by levels of estradiol-17/3 (E2) on cycle day 3. Design: Prospective cohort study. Setting: University hospital-based, tertiary care infertility center. Patient(s): Two hundred thirty-one consecutively seen patients who attended the center for their first IVF attempt. Intervention(s): Blood samples were collected on day 3 of the cycle preceding IVF; IVF was performed in all patients. Main Outcome Measure(s): Patient's age, number of ampules of hmg, cancellation rate, number of oocytes, fertilization rate, and clinical pregnancy rate. Result(s): In patients with elevated FSH levels on cycle day 3, a low oocyte yield was achieved (7 versus 11) and a high number of ampules of hmg was necessary (56 versus 33). Their cancellation rate was high (67% versus 16%). In patients with normal basal FSH levels, high E 2 levels predicted a high cancellation rate (56%, versus 13% in patients with low E 2 levels) and a low oocyte yield (9, versus l 1 in patients with low E 2 levels). Patients with both normal FSH levels and low E 2 levels on cycle day 3 fared best. Conclusion(s): The basal E 2 level on cycle day 3 is a useful prognosticator of response to stimulation in IVF patients with normal basal FSH levels. (Fertil Steril 1998;69: by American Society for Reproductive Medicine.) Key Words: Poor response, IVF prognosis, basal estradiol-17/3 (E2), CD a Ea, basal FSH, CD 3 follicle-stimulating hormone (FSH) Received September 8, 1997; revised and accepted January 5, Reprint requests: Johannes L. H. Evers, M.D., Department of Obstetrics and Gynecology, Academisch Ziekenhuis Maastricht, P.O. Box 5800, NL 6202 AZ Maastricht, The Netherlands (FAX: ) /98/$19.00 PII S (98) The basal FSH level has proved to be a reliable prognosticator of IVF outcome (1-3). Muasher et al. (1) concluded that on the third day of the menstrual cycle, FSH levels could differentiate populations with poor stimulation characteristics from those with good stimulation characteristics. Scott et al. (2) observed that if patients had an FSH level of ->15 miu/ml (Second International Reference Preparation [IRP] hmg standard) on cycle day 3, fewer pregnancies occurred, and if the FSH level was ->25 miu/ml, no pregnancies occurred. Toner et al. (3) determined that the FSH level on cycle day 3 was a better indicator of IVF outcome than age. Licciardi et al. (4) found that in cycles in which a GnRH agonist (GnRH-a) was not given, high levels of estradiol-17/3 (E2) on cycle day 3 were associated with low oocyte yields and low pregnancy rates (PRs). They obtained significantly fewer oocytes in patients with elevated E 2 levels (>60 pg/ml) on cycle day 3. No pregnancies occurred in patients with basal FSH levels of > 17 miu/ml if their basal E 2 level was >45 pg/ml. Smotrich et al. (5) confirmed that patients with elevated E 2 levels on cycle day 3 (in a cycle preceding IVF) had a higher cancellation rate and a lower PR, independent of FSH levels, than patients with low E 2 levels on cycle day

2 We performed this study to validate the findings of Licciardi et al. (4) in an unstimulated cycle preceding IVF. If the findings of these investigators were also proven valid for patients in whom blood samples were obtained in a spontaneous cycle before IVF, this would allow more appropriate selection and counseling of patients for IVF. We studied an independent set of patients but used the same cutoff levels for E 2 (60 pg/ml) and FSH (17 miu/ml) on cycle day 3. Our hypothesis was that on cycle day 3, FSH levels of >17 miu/ml (Second IRP standard; equal to > 10 miu/ml using the World Health Organization 78/549 calibration standard [6]) identify patients who respond poorly in IVF and that E 2 levels of >60 pg/ml on cycle day 3 help to differentiate between good and intermediate responders in a group with normal basal FSH levels (---17 miu/ml). MATERIALS AND METHODS The study population consisted of 231 consecutive IVF patients who had not previously undergone a stimulation cycle. Only first IVF stimulation cycles were included in this study. Patients who received donor oocytes or micromanipulated oocytes were excluded. At the time of this investigation, the license to perform IVF in our country depended on achieving an ongoing PR of --> 10% per cycle started. Therefore, a need existed for early (pretreatment) identification of potential poor responders. So far, only age (<40 years) and basal FSH level (<34 miu/ml) have been applied as inclusion criteria for admission into our IVF program. No further selection was performed in the patient group of this study. Our stimulation regimen has been published before (6). In short, all cycles were stimulated using hmg (Humegon; Organon, Oss, The Netherlands; or Pergonal; Serono, The Hague, The Netherlands) in combination with intranasal administration of a GnRH-a (Suprefact, buserelin, 300 /~g t.i.d.; Hoechst, Frankfurt, Germany; or Synarel, nafarelin, 400 ~g b.i.d.; Searle, Maarssen, the Netherlands). After suppression of ovarian activity with the GnRH-a for ->12 days (long protocol), hmg therapy was started. In their first cycle, all patients received a fixed-dose regimen of three ampules (225 IU) of hmg as a single daily injection. Follicular growth was assessed by transvaginal ultrasonography, with follicular diameter representing the arithmetic mean of three perpendicular dimensions. No hormone levels were monitored. According to National Health Service regulations, patients in The Netherlands are entitled to receive three IVF cycles free of charge. In our clinic, in first IVF attempts, the administration of hmg is discontinued if insufficient follicles develop (<4 follicles with a diameter of -> 16 mm after 12 days of stimulation; this was adopted as the definition of poor response in the present study). As soon as four or more follicles reached a mean diameter of -->18 mm each, hcg (5,000 IU, Pregnyl; Organon; or Profasi; Serono) was administered. At this time, hmg and GnRH-a were discontinued. Oocyte retrieval was performed under vaginal ultrasonographic guidance hours after hcg administration. The transfer of two or sometimes three embryos to the uterus was scheduled for hours after insemination. The luteal phase was supported by vaginal progesterone suppositories (2 100 mg t.i.d., Progestan, micronized progesterone; Organon). A clinical pregnancy was defined as ultrasonographic evidence of intrauterine fetal heart activity 5 weeks after ET. Levels of FSH and E 2 on cycle day 3 were determined in a spontaneous cycle preceding the cycle of stimulation. We recorded the patient's age, number of days of stimulation, total number of ampules administered, number of oocytes retrieved, cancellation rate (number of cycles abandoned divided by number of cycles started), fertilization rate (number of oocytes fertilized divided by number of oocytes retrieved), and clinical PR (number of pregnancies with fetal heart activity 5 weeks after ET divided by number of cycles started). We measured FSH with a commercially available RIA (Delfia; Wallac Oy, Turku, Finland). The sensitivity of the FSH assay was miu/ml, calibrated to the Second IRP standard. The intra-assay and interassay coefficients of variation were <4%. A special problem occurs in comparing the results of FSH determinations because of the use of different reference preparations to calibrate the respective assays. Our cutoff level of 10 miu/ml of FSH, calibrated to World Health Organization standard 78/549 and widely used in Europe, equals a level of 17 mlu/ml if the assay is calibrated against the Second IRP, widely used in the United States (6). In the present study, FSH values are expressed as calibrated to the Second IRP standard. Estradiol levels also were measured by a commercially available double-antibody RIA (Coat-A-Count; Diagnostic Products Corporation, Los Angeles, CA). The sensitivity of the E 2 assay was 9.5 pg/ml. The intra-assay and interassay coefficients of variation were < 14%. Statistical analysis was performed with use of the Student's t-test and the X 2 test or Fisher's exact probability test. P<0.05 was defined as statistical significance. Data are expressed as means _+ standard deviations, medians and ranges, or means and 95% confidence interval (CI), whichever is appropriate. Diagnostic test evaluation included risk ratio and likelihood ratio estimations for positive and negative test results, considering FSH and E 2 determinations as independent diagnostic tests. Written informed consent was obtained from each patient for the anonymous use of data from their IVF cycles. Institutional Review Board approval is not required for chart reviews in The Netherlands. FERTILITY & STERILITY 1011

3 Stimulation and IVF outcome for all 231 patients according to FSH concentrations on cycle day 3. Group 1: Group 2: FSH <--17 miu/ml FSH >17 mlu/ml Variable (n = 213) (n = 18) P value Mean (_+SD) patient age (y) Mean percentage of poor responders (95% CI)* Mean ( total no. of ampules Mean ( no. of oocytes retrieved Mean (_+SD) fertilization rate (%)? Mean percentage of pregnancies/opu (95% CI):~ Mean clinical PR (%) (95% CI)w 33 _ < (11-21) 67 (41-87) < < < _ _+ 24 NS 20 (14-26) 0 (046) NS 15 (10-22) 0 (0-19) NS Note: NS = not significant. * Fewer than four follicles with a diameter of -->16 mm after 12 days of stimulation.? Fertilization rate = number of oocytes with two pronnclei divided by number of oocytes retrieved, multiplied by 100%. Pregnancies/OPU = number of pregnancies with fetal heart activity 5 weeks after ET divided by number of ovum pickup procedures. w Clinical PR = number of pregnancies with fetal heart activity 5 weeks after ET divided by number of cycles started, multiplied by 100%. RESULTS Table 1 shows the stimulation and cycle outcome data according to FSH levels on cycle day 3. In all, 213 patients (group 1) had FSH levels of -<17 miu/ml (median, 10.1; range, miu/ml), and 18 patients (group 2) had FSH levels of > 17 miu/ml (median, 20.7; range, miu/ml). Patients with FSH levels of miu/ml on cycle day 3 were not accepted into the program. In group 1 (normal FSH levels), 35 cycles were canceled because of poor response (16%) and 32 patients became pregnant (15%). In group 2 (high FSH levels), 12 cycles were canceled (67%) and no patient became pregnant. The mean patient age differed significantly (P<0.005) between the groups. Patients in group 1 (normal FSH levels) needed significantly less stimulation (lower total ampules of hmg), had significantly more oocytes retrieved, and had significantly fewer cycles canceled than group 2 patients (high FSH levels). To study the potential contribution of the E 2 level on cycle day 3 to the prediction of IVF outcome, we subdivided group 1 patients (normal FSH levels) according to their E 2 level on cycle day 3: group 1A (low E 2 level, i.e., -<60 pg/ml) and group 1B (high E 2 level, i.e., >60 pg/ml). The stimulation and outcome data for these patients are shown in Table 2. The 197 patients with a low E 2 level (group 1A) had a median E 2 level of 30 pg/ml (range, < pg/ml), with 26 cancellations (13%) and 32 pregnancies (16%). Group 1B (high E 2 level) consisted of 16 patients with a median E 2 level of 74 pg/ml (range, pg/ml), with 9 cancellations (56%) and no pregnancies. The mean patient age did not differ between these groups. Group 1A (normal FSH levels, low E 2 levels) had significantly more oocytes retrieved and significantly fewer cycles canceled than group 1B (normal FSH levels, high E 2 levels) (Table 2). The differences in total number of ampules administered, fertilization rates, and PRs did not reach statistical significance. Because no pregnancies occurred in the 18 patients in group 2 (high FSH levels), no further breakdown according to their basal E 2 levels was performed. All patients in this group had E 2 levels of --<60 pg/ml. Considering FSH and E 2 determinations as independent tests for the prediction of poor response in an IVF treatment cycle, patients with FSH levels of >17 miu/ml were 4.1 times more likely (relative risk) to have their first IVF treatment cycle abandoned (95% CI, ) than patients with FSH levels of -< 17 miu/ml. The likelihood ratio of an abnormal test was 7.8 (95% CI, ), indicating that an FSH level of >17 miu/ml was 7.8 times more likely to be found in a patient who was going to have treatment abandoned in her first cycle than in a patient who would proceed to oocyte retrieval. For patients with normal FSH levels (-<17 miu/ml), the risk that their first treatment cycle would be abandoned if their basal E 2 level was >60 pg/ml was 4.3 times (95% CI, ) the risk of patients with normal FSH levels and basal E 2 levels of --<60 pg/ml. The likelihood ratio of an abnormal test for the basal E 2 determination as a diagnostic test was 6.5 (95% CI, ), indicating that an E 2 level of >60 pg/ml was 6.5 times more likely to be found in a patient who was going to have treatment abandoned in her first cycle than in a patient proceeding to oocyte retrieval. In clinical medicine, a likelihood ratio of an abnormal test of >5.0 is considered to reflect a useful diagnostic test. In the population studied, with an overall prevalence of 20% for poor response (<4 follicles with a diameter of >--16 mm after 12 days of stimulation), high FSH levels correctly predicted poor response to stimulation in 67% of the patients. High E 2 levels correctly predicted poor response in 56% of those patients who had normal FSH levels Evers et al. Basal E 2 and response in IVF patients Vol. 69, No. 6, June 1998

4 Stimulation and IVF outcome accordin9 to E z concentrations on cycle day 3 for those 2]3 patients (StOUp ]) who had FSH levels of _<]7 mlu/mt_ on cycle day 3. Group IA: Group 1B: E 2 --<60 pg/ml E 2 >60 pg/ml Variable (n = 197) (n = 16) P value Mean (_+SD) patient age (y) Mean percentage of poor responders (95% CI)* Mean (_+SD) total no. of ampules Mean (+SD) no. of oocytes retrieved Mean (-+SD) fertilization rate (%)? Mean percentage of pregnancies/opu (95% CI):~ Mean clinical PR (%) (95% CI)w 33 +_ NS 13 (8-18) 56 (30-80) < _ NS < _+ 30 NS 20 (14-27) 0 (0-52) NS 16 (11-21) 0 (0-21) NS Note: NS = not significant. Group 1 patients are described in Table 1. * Fewer than four follicles with a diameter of ->16 mm after 12 days of stimulation. 1- Fertilization rate = number of oocytes with two pronuclei divided by number of oocytes retrieved, multiplied by 100%. :~ Pregnancies/OPU = number of pregnancies with fetal heart activity 5 weeks after ET divided by number of ovum pickup procedures. w Clinical PR = number of pregnancies with fetal heart activity 5 weeks after ET divided by number of cycles started, multiplied by 100%. DISCUSSION In the present study, we confirmed that the FSH level on cycle day 3 in a spontaneous cycle preceding IVF is a good prognosticator of a patient's response to stimulation in a subsequent IVF cycle, in which hmg stimulation is performed during GnRH-a down-regulation (long protocol). The group with a high FSH level on cycle day 3 had an increased need for hmg (56 ampules, compared with 33 in patients with a normal FSH level), a poor response to stimulation (67% cancellations versus 16%), and a diminished oocyte yield (7 versus 11 per oocyte pickup procedure). Within the group with a normal FSH level on cycle day 3, those patients who showed a high E 2 level had a poor response to stimulation (56% cancellations) and an intermediate oocyte yield (9 per oocyte pickup procedure). The group with both a normal FSH level and a low E 2 level on cycle day 3 showed an appropriate response to stimulation (13% cancellations) and a good yield (11 oocytes). As women progress through reproductive life, ovarian reserves decline. This is reflected in increasing basal FSH levels in the early follicular phase of the menstrual cycle (7). The pituitary gland will increase FSH output in an effort to maintain a normal follicular response. In parallel to this increased demand for endogenous FSH, the response to exogenous FSH during (multiple) ovulation induction treatment is impaired (6). Estradiol, a steroid hormone produced by granulosa cells, and inhibin, a peptide hormone also of granulosa cell origin, have been implicated in the negative feedback relation between the developing follicle and the pituitary, although the role of inhibin awaits more detailed research (7). Seifer et al. (8) showed that women with low serum inhibin-b levels on cycle day 3 responded poorly to ovarian stimulation and that the outcome of assisted reproduction was poor for these women. Hughes et al. (9) found an age-related reduction of inhibin response, but not E 2 response, to ovarian stimulation. This may indicate that pituitary FSH release in women of advancing reproductive age is less restrained than in young women by factors from the granulosa cell-oocyte complex (7). In these women, loss of inhibin-mediated feedback inhibition of the pituitary will result in increased FSH output and a secondary increase in E 2 production by the ovaries. This in turn will suppress FSH production and release. A new balance between pituitary stimulus and ovarian response will result, reflected in normal FSH levels at the expense of increased circulating E 2. Apparently this new balance is temporary. Further progression toward menopause and aging of the ovary will be accompanied by decreased E 2 levels in the early follicular phase and a concomitant rise in FSH levels, as reflected in our group of patients with elevated FSH levels, all of whom had low E 2 levels. The findings of the present study confirm, in an independent group of patients before the start of IVF, earlier findings by Licciardi et al. (4) that FSH levels of >17 mlu/ml on cycle day 3 predict an impaired ovarian response in patients with a regular menstrual cycle and that within the group with normal FSH levels, E 2 levels may help predict the response to stimulation. In this group, E 2 levels of >60 pg/ml indicated a higher chance of poor response and a lower oocyte yield after ovum pickup. Patients with high FSH levels (> 17 mlu/ml) should be counseled that their risk of having a poor response in their first treatment cycle is 4.1 times the risk in patients with normal FSH levels and that if their basal FSH level is normal but they have increased basal E 2 levels, their risk of poor response is 4.3 times the risk of patients with both normal FSH levels and low E 2 levels. FERTILITY & STERILITY 1013

5 In conclusion, an elevated FSH level on cycle day 3 is a useful prognosticator of poor response to stimulation in prospective IVF patients. Estradiol levels on cycle day 3 are of added value for counseling patients with normal basal FSH levels or for explaining an unexpectedly poor outcome in a patient with a normal basal FSH level who has already undergone an IVF attempt. Unfortunately, patients who re- spond poorly to a stimulation dose of three ampules of hmg per day do not fare better in a subsequent stimulation cycle if the daily dose is increased to six ampules (6). References 1. Muasher SJ, Oehninger S, Simonetti S, Matta J, Ellis LM, Liu HC, et al. The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil Steril 1988;50: Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989;5l: Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991;55: Licciardi FL, Liu HC, Rosenwaks Z. Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 1995; 64: Smotrich DB, Widra EA, Gindoff PR, Levy MJ, Hall JL, Stillman RJ. Prognostic value of day 3 estradiol on in vitro fertilization outcome. Ferfil Steril 1995;64: Land JA, Yarmolinskaya MI, Dumoulin JCM, Evers JLH. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996;65: Lenton EA, De Kretser DM, Woodward AJ, Robertson DM. Inhibin concentrations throughout the menstrual cycles of normal, infertile, and older women compared with those during spontaneous conception cycles. J Clin Endocrinol Metab 1991 ;73: Seifer DB, Gardiner AC, Lambert-Messerlian G. Day 3 serum inhibin-b is predictive of assisted reproductive technologies outcome. Fertil Steril 1997;67: Hughes EG, Robertson DM, Handelsman DJ, Hayward S, Healy DL, de Kretser DM. Inhibin and estradiol responses to ovarian hyperstimulation: effects of age and predictive value for in vitro fertilization outcome. J Clin Endocrinol Metab 1990;70: Evers et al. Basal E 2 and response in IVF patients Vol. 69, No. 6, June 1998

Timur Giirgan, M.D.* Bulent Urman, M.D. Hakan Yarali, M.D. Hakan E. Duran, M.D.

Timur Giirgan, M.D.* Bulent Urman, M.D. Hakan Yarali, M.D. Hakan E. Duran, M.D. FERTILITY AND STEFULI~ Vol. 68, No. 3, September 1997 Copyright 1997 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Published by Elsevier Science Inc. Follicle-stimulating

More information

Evaluation of basal estradiol levels in assisted reproductive technology cycles

Evaluation of basal estradiol levels in assisted reproductive technology cycles FERTILITY AND STERILITY VOL. 74, NO. 3, SEPTEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Evaluation of basal

More information

Prognostic value of day 3 estradiol on in vitro fertilization outcome*

Prognostic value of day 3 estradiol on in vitro fertilization outcome* FERTILITY AND STERILITY Vol. 64, No.6, December 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Prognostic value of day 3 estradiol on in vitro fertilization

More information

Ovarian response in three consecutive in vitro fertilization cycles

Ovarian response in three consecutive in vitro fertilization cycles FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in

More information

Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization*

Intercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization* FERTILITY AND STERILITY Copyright C> 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Inter variability of day 3 follicle-stimulating hormone levels and its effect on stimulation

More information

Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome

Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome British Journal of Obstetrics and Gynaecology January 1998, Vol. 105, pp. 107-1 12 Age and basal follicle stimulating hormone as predictors of in vitro fertilisation outcome Khaldoun Sharif Lecturer, Manal

More information

Elena H. Yanushpolsky, M.D., a Shelley Hurwitz, Ph.D., b Eugene Tikh, B.S., c and Catherine Racowsky, Ph.D. a

Elena H. Yanushpolsky, M.D., a Shelley Hurwitz, Ph.D., b Eugene Tikh, B.S., c and Catherine Racowsky, Ph.D. a FERTILITY AND STERILITY VOL. 80, NO. 1, JULY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Predictive usefulness of cycle

More information

IVF Performance of Women Who Have Fluctuating Early Follicular FSH Levels 1

IVF Performance of Women Who Have Fluctuating Early Follicular FSH Levels 1 CLINICAL ASSISTED REPRODUCTION IVF Performance of Women Who Have Fluctuating Early Follicular FSH Levels 1 A. LASS, 2,3 A. GERRARD, 2 N. ABUSHEIKHA, 2 F. AKAGBOSU, 2 and P. BRINSDEN 2 Submitted: April

More information

Article Evaluation of functional ovarian reserve in 60 patients

Article Evaluation of functional ovarian reserve in 60 patients RBMOnline - Vol 7. No 2. 200 204 Reproductive BioMedicine Online; www.rbmonline.com/article/846 on web 12 June 2003 Article Evaluation of functional ovarian reserve in 60 patients Dr Giuseppe Loverro Giuseppe

More information

IN VITRO FERTILIZATION

IN VITRO FERTILIZATION FERTILITY AND STERILITY VOL. 82, NO. 4, OCTOBER 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. IN VITRO FERTILIZATION Prognostic

More information

IN VITRO FERTILIZATION

IN VITRO FERTILIZATION FERTILITY AND STERILITY VOL. 79, NO. 1, JANUARY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. IN VITRO FERTILIZATION

More information

Significance of basal follicle-stimulating hormone levels in women with one ovary in a program of in vitro fertilization*

Significance of basal follicle-stimulating hormone levels in women with one ovary in a program of in vitro fertilization* FERTILITY AND STERILITY Copyright e 1992 The American Fertility Society Printed on acid-free paper in U.S.A. Significance of basal follicle-stimulating hormone levels in women with one ovary in a program

More information

lbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour

lbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate

More information

Estradiol Level on Day 2 and Day of Trigger: A Potential Predictor of the IVF-ET Success

Estradiol Level on Day 2 and Day of Trigger: A Potential Predictor of the IVF-ET Success DOI 10.1007/s13224-014-0515-6 ORIGINAL ARTICLE Estradiol Level on Day 2 and Day of Trigger: A Potential Predictor of the IVF-ET Success Prasad Sudha Kumar Yogesh Singhal Megha Sharma Shashi Received: 27

More information

Correlation of the Day 3 FSH/LH Ratio and LH Concentration in Predicting IVF Outcome

Correlation of the Day 3 FSH/LH Ratio and LH Concentration in Predicting IVF Outcome Original Article Correlation of the Day 3 FSH/LH Ratio and LH Concentration in Predicting IVF Outcome Sudha Prasad 1*, Teena Gupta 1, Aabha Divya 2 1- IVF and Reproductive Biology Centre, Department of

More information

Endocrinology of the Female Reproductive Axis

Endocrinology of the Female Reproductive Axis Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN

More information

LOW RESPONDERS. Poor Ovarian Response, Por

LOW RESPONDERS. Poor Ovarian Response, Por LOW RESPONDERS Poor Ovarian Response, Por Patients with a low number of retrieved oocytes despite adequate ovarian stimulation during fertility treatment. Diagnosis Female About Low responders In patients

More information

Utility of in vitro fertilization at diagnostic laparoscopy*

Utility of in vitro fertilization at diagnostic laparoscopy* FERTILITY AND STERILITY Copyright" 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Utility of in vitro fertilization at diagnostic laparoscopy* Paul R. Gindoff, M.D.t Jerry L.

More information

Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation

Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation Human Reproduction vol.8 no.9 pp. 1387-1391, 1993 Different follicle stimulating hormone/luteinizing hormone ratios for ovarian stimulation LJ.M.Duijkers 1 ' 4, H.M.Vemer 1, J.M.G.HoUanders 1, W.N.P.Willemsen

More information

Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization

Milder is better? Advantages and disadvantages of mild ovarian stimulation for human in vitro fertilization Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background

More information

Ovulation induction in women age 40 and older: the importance of basal follicle-stimulating hormone level and chronological age*

Ovulation induction in women age 40 and older: the importance of basal follicle-stimulating hormone level and chronological age* FERTILITY AND STERILITY Vol. 58, No.4, October 1992 Copyright It! 1992 The American Fertility Society Printed on acid-free paper in U. S.A. Ovulation induction in women age 40 and older: the importance

More information

I. ART PROCEDURES. A. In Vitro Fertilization (IVF)

I. ART PROCEDURES. A. In Vitro Fertilization (IVF) DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24875

More information

Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol

Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Yamanashi Med. J. 14(3), 77 ~ 82, 1999 Original Article Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Tsuyoshi KASAI and Kazuhiko

More information

In Vitro Fertilization and Embryo Transfer

In Vitro Fertilization and Embryo Transfer Acta Medica et Biologica Vol. 41, No.4, 171-176, 1993 The Influence of Low Ovarian Response on the Results of In Vitro Fertilization and Embryo Transfer Hirofumi HIRASAWA Department of Obstetrics and Gynecology,

More information

Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer

Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer Mohamed F. Mitwally, M.D., H.C.L.D., a Michael P. Diamond,

More information

IT IS NOW recognized that inhibin plays an important

IT IS NOW recognized that inhibin plays an important 0021-972X/00/$03.00/0 Vol. 85, No. 2 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2000 by The Endocrine Society Relationship between Serum Inhibin A and B and Ovarian

More information

Cigarette smoking accelerates the development of diminished ovarian reserve as evidenced by the clomiphene citrate challenge test*

Cigarette smoking accelerates the development of diminished ovarian reserve as evidenced by the clomiphene citrate challenge test* FERTILITY AND STERILITY Copyright @ 1994 The American Fertility Society Printed on acid-free paper in U. s. A. Cigarette smoking accelerates the development of diminished ovarian reserve as evidenced by

More information

The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins

The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing

More information

Luteal phase rescue after GnRHa triggering Progesterone and Estradiol

Luteal phase rescue after GnRHa triggering Progesterone and Estradiol Luteal phase rescue after GnRHa triggering Progesterone and Estradiol L. Engmann University of Connecticut Disclaimer Fertility Speaker Bureau Merck Pharmaceuticals Introduction GnRH agonist is effective

More information

Follicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation

Follicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation Follicle-stimulating hormone/luteinizing hormone ratio as an independent predictor of response to controlled ovarian stimulation Aim: To determine whether a follicle-stimulating hormone (FSH)/luteinizing

More information

Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *

Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed

More information

Assisted reproductive technology

Assisted reproductive technology Assisted reproductive technology FERTILITY AND STERILITY Vol. 60, No.2, August 1993 Copyright 'c; 199:~ The American Fertility Society Printed on acid-free paper in U. S. A. Natural cycle in vitro fertilization-embryo

More information

Rafael A. Cabrera, M.D., Laurel Stadtmauer, M.D., Ph.D., Jacob F. Mayer, Ph.D., William E. Gibbons, M.D., and Sergio Oehninger, M.D., Ph.D.

Rafael A. Cabrera, M.D., Laurel Stadtmauer, M.D., Ph.D., Jacob F. Mayer, Ph.D., William E. Gibbons, M.D., and Sergio Oehninger, M.D., Ph.D. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant

More information

Infertility treatment

Infertility treatment In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation

More information

10.7 The Reproductive Hormones

10.7 The Reproductive Hormones 10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid

More information

Gn-RH Agonist Challenge Test for Predicting Ovarian Reserve in Short Protocol Cycles

Gn-RH Agonist Challenge Test for Predicting Ovarian Reserve in Short Protocol Cycles J Obstet Gynecol lnd Vol. 54, No.1: January/February 2004 Pg 51-55 Gn-RH Agonist Challenge Test for Predicting Ovarian Reserve in Short Protocol Cycles Ocal Pelin, Cepni Ismail, Akbas Hande, Idil Mehmet,

More information

Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest

Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.

More information

Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?

Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles? J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation

More information

Female Reproductive System. Lesson 10

Female Reproductive System. Lesson 10 Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System

More information

Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M

Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic

More information

Neil Goodman, MD, FACE

Neil Goodman, MD, FACE Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects

More information

A prospective randomized study comparing aspiration only with aspiration and flushing for transvaginal ultrasound-directed oocyte recovery

A prospective randomized study comparing aspiration only with aspiration and flushing for transvaginal ultrasound-directed oocyte recovery FERTILITY AND STERILITY Vol. 58, No.2, August 1992 Copyright e 1992 The American Fertility Society Printed on acid-free paper in U.S.A. A prospective randomized study comparing aspiration only with aspiration

More information

Summary

Summary Summary 118 This thesis is focused on the background of elevated levels of FSH in the early follicular phase of women with regular menstrual cycles. In the introduction (chapter 1) we describe the characteristics

More information

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,

More information

Article Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles

Article Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles RBMOnline - Vol 6. No 4. 439 443 Reproductive BioMedicine Online; www.rbmonline.com/article/872 on web 7 April 2003 Article Conception rates following assisted reproduction in poor responder patients:

More information

Prognosticating ovarian reserve by the new ovarian response prediction index

Prognosticating ovarian reserve by the new ovarian response prediction index International Journal of Reproduction, Contraception, Obstetrics and Gynecology Tak A et al. Int J Reprod Contracept Obstet Gynecol. 2018 Mar;7(3):1196-1200 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20180917

More information

IVF treatment should not be postponed for patients with high basal FSH concentrations

IVF treatment should not be postponed for patients with high basal FSH concentrations Reproductive BioMedicine Online (2010) 21, 631 635 www.sciencedirect.com www.rbmonline.com SHORT COMMUNICATION IVF treatment should not be postponed for patients with high basal FSH concentrations Ettie

More information

IOF POI. hypergonadotropic hypogonadism primary ovarian insufficiency POI /premature ovarian failure POF. Van Kasteren. Coulam POI FSH E.

IOF POI. hypergonadotropic hypogonadism primary ovarian insufficiency POI /premature ovarian failure POF. Van Kasteren. Coulam POI FSH E. hypergonadotropic hypogonadism primary ovarian insufficiency POI /premature ovarian failure POF Coulam POI Turner Fragile X premutation FSHR NOBOX FOXL etc POI FSH miu/ml AMH AMH AMH FSH / Knauff POI IOF

More information

IVF Protocols: Hyper & Hypo-Responders, Implantation

IVF Protocols: Hyper & Hypo-Responders, Implantation IVF Protocols: Hyper & Hypo-Responders, Implantation Midwest Reproductive Symposium June 4-5, 4 2010 Subset : Hyper-Responders Mark R. Bush, MD, FACOG, FACS OBJECTIVE: Important goals for the PCOS patient

More information

Utility of color Doppler indices of dominant follicular

Utility of color Doppler indices of dominant follicular Ultrasound Obstet Gynecol 2002; 20: 592 596 Utility of color Doppler indices of dominant follicular Blackwell Science, Ltd blood flow for prediction of clinical factors in in vitro fertilization-embryo

More information

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve

More information

2017 United HealthCare Services, Inc.

2017 United HealthCare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017

More information

N.A.Bersinger 1, A.Brandenberger, E.Berger, C.K.Baumann and M.H.Birkhäuser

N.A.Bersinger 1, A.Brandenberger, E.Berger, C.K.Baumann and M.H.Birkhäuser Human Reproduction vol.13 no.7 pp.1962 1967, 1998 Serum pregnancy-specific β 1 -glycoprotein before embryo transfer is related to endometrial thickness and to outcome prognosis in women undergoing in-vitro

More information

WOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IVF WITH EMBRYO TRANSFER

WOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IVF WITH EMBRYO TRANSFER *40639* 40639 WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IVF WITH EMBRYO TRANSFER I have requested treatment by the physicians and (Print Patient s name) staff of the Women & Infants Fertility

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Infertility Injectables Table of Contents Coverage Policy... 1 General Background...16 Coding/Billing Information...20 References...20 Effective Date...

More information

Department of Obstetrics and Gynecology, Changhua Christian Hospital, Institute of Medical Research, Chang Jung University, Changhua 500, Taiwan

Department of Obstetrics and Gynecology, Changhua Christian Hospital, Institute of Medical Research, Chang Jung University, Changhua 500, Taiwan Endocrine Journal 2005, 52 (4), 407 412 Relationship between Sex Hormone-Binding Globulin and Pregnancy Outcome in Women Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproduction KUO-CHERNG

More information

Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY

Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY Endometrial Preparation for Frozen Embryo Transfer (FET) Zitao Liu, MD, PhD New Hope Fertility Center, NY Natural Cycle FET Protocol for endometrial preparation N FET, including modified N FET HRT FET:

More information

Progesterone and clinical outcomes

Progesterone and clinical outcomes Synchronization of Slowly Developing Embryos Restores Implantation Success Richard T. Scott, Jr, MD, HCLD Clinical and Scientific Director, Reproductive Medicine Associates of New Jersey Professor and

More information

Superovulation with human menopausal gonadotropins is associated with endometrial gland-stroma dyssynchrony*

Superovulation with human menopausal gonadotropins is associated with endometrial gland-stroma dyssynchrony* aes FERTILITY AND STERILITY Vol. 61, No.4, April 1994 Copyright ee) 1994 The American Fertility Society Printed on acid-free paper in U. S. A. r I Superovulation with human menopausal gonadotropins is

More information

Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy

Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy Ovarian Response to Gonadotrophin Stimulation in Patients with Previous Endometriotic Cystectomy M.E. Coccia, F. Cammilli, L. Ginocchini, F. Borruto* and F. Rizzello Dept Gynaecology Perinatology and Human

More information

Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles

Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist

More information

Serum Estradiol Level as a Predictor of Ovarian Response and Pregnancy Outcome During Controlled Ovarian Hyperstimulation in Women from Gaza Strip

Serum Estradiol Level as a Predictor of Ovarian Response and Pregnancy Outcome During Controlled Ovarian Hyperstimulation in Women from Gaza Strip J MEDICINE 2013; 14 : 52-56 Serum Estradiol Level as a Predictor of Ovarian Response and Pregnancy Outcome During Controlled Ovarian Hyperstimulation in Women from Gaza Strip MAGED M. YASSIN, 1 MOHAMMED

More information

N. Shirazian, MD. Endocrinologist

N. Shirazian, MD. Endocrinologist N. Shirazian, MD Internist, Endocrinologist Inside the ovary Day 15-28: empty pyfollicle turns into corpus luteum (yellow body) Immature eggs Day 1-13: 13: egg developing inside the growing follicle Day

More information

University of Groningen. Female reproductive ageing Haadsma, Maaike Laura

University of Groningen. Female reproductive ageing Haadsma, Maaike Laura University of Groningen Female reproductive ageing Haadsma, Maaike Laura IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the

More information

Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older

Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older Reprod Med Biol (2009) 8:145 149 DOI 10.1007/s12522-009-0023-z ORIGINAL ARTICLE Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older Akihisa

More information

A Tale of Three Hormones: hcg, Progesterone and AMH

A Tale of Three Hormones: hcg, Progesterone and AMH A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan

More information

Best practices of ASRM and ESHRE

Best practices of ASRM and ESHRE Best practices of ASRM and ESHRE Late submission Cortina d Ampezzo, Italy 1-3 March 2012 A joint meeting between the American Society for Reproductive Medicine and the European Society of Human Reproduction

More information

IVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)

IVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn) 34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh

More information

Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.

Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. UvA-DARE (Digital Academic Repository) Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H. Link to publication Citation for published version (APA): Mochtar, M. H.

More information

The association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age

The association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age Reproductive BioMedicine Online (2010) 21, 757 761 www.sciencedirect.com www.rbmonline.com ARTICLE The association between anti-müllerian hormone and IVF pregnancy outcomes is influenced by age Jeff G

More information

The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study

The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi

More information

Antagonists in poor-responder patients

Antagonists in poor-responder patients FERTILITY AND STERILITY VOL. 80, SUPPL. 1, JULY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Antagonists in poor-responder

More information

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen? CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,

More information

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare Carlo Alviggi The rational of Follicular synchronization

More information

Bulent Urman, M.D.* Margo R. Fluker, M.D. Basil Ho Yuen, M.B., Ch.B.t

Bulent Urman, M.D.* Margo R. Fluker, M.D. Basil Ho Yuen, M.B., Ch.B.t FERTILITY AND STERILITY Copyright c 1992 The American Fertility Society Vol. 57, No.6, June 1992 Printed on acid-free paper in U.S.A. The outcome of in vitro fertilization and embryo transfer in women

More information

Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation

Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation RBMOnline - Vol 16. No 6. 2008 772-777 Reproductive BioMedicine Online; www.rbmonline.com/article/3181 on web 18 April 2008 Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation

More information

The effects of prior gravidity on the outcomes of ovum donor and own oocyte cycles

The effects of prior gravidity on the outcomes of ovum donor and own oocyte cycles FERTILITY AND STERILITY Vol. 65, No.3, March 1996 Copyright t';, 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. s. A. The effects of prior gravidity on the outcomes of

More information

A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates

A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates Micah J. Hill, D.O., a Grant D. E. McWilliams, D.O., b Kathleen A. Miller, B.S., c Richard T. Scott, Jr, M.D.,

More information

Relation between the Number and Size of Follicles in Ovulation Induction and the Rate of Pregnancy

Relation between the Number and Size of Follicles in Ovulation Induction and the Rate of Pregnancy Relation between the Number and Size of Follicles in Ovulation Induction and the Rate of Pregnancy Aseel Mosa Jabber M.SC.G.O. The department of Obstetrics and Gynecology, Faculty of Medicine Thi-qar university

More information

Medicine, Al-Nahrain University

Medicine, Al-Nahrain University Iraqi JMS Published by Al-Nahrain College of Medicine ISSN 1681-6579 Email: iraqijms@colmed-alnahrain.edu.iq http://www.colmed-alnahrain.edu.iq Relation of Antimüllerian, Follicular Stimulating Hormone

More information

Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.

Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,

More information

Infertility Clinical Guideline

Infertility Clinical Guideline Infertility Clinical Guideline Ovarian Stimulation Guideline Purpose: To provide sufficient background regarding various ovarian stimulation protocols for In Vitro Fertilization cycles. Goal: To assist

More information

Duration of progesterone-in-oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial

Duration of progesterone-in-oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial Duration of progesterone-in-oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial Christine S. Goudge, M.D., Theodore C. Nagel, M.D., and Mark A. Damario, M.D. Division

More information

WOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1.

WOMEN & INFANTS HOSPITAL Providence, RI CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1. *40675* 40675 MR-838 (9-2017) WOMEN & INFANTS HOSPITAL Providence, RI 02905 CONSENT FOR IN VITRO FERTILIZATION USING A GESTATIONAL CARRIER (PATIENT/INTENDED PARENTS) 1. I, and (Print Patient s name) (Print

More information

Risk factors for spontaneous abortion in menotropintreated

Risk factors for spontaneous abortion in menotropintreated FERTILITY AND STERILITY Copyright ~ 1987 The American Fertility Society Vol. 48, No. 4, October 1987 Printed in U.S.A. Risk factors for spontaneous abortion in menotropintreated women Michael Bohrer, M.D.*

More information

Ovarian age-based stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization

Ovarian age-based stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization Ovarian age-based stimulation of young women with diminished ovarian reserve results in excellent pregnancy rates with in vitro fertilization Norbert Gleicher, M.D., and David Barad, M.D. Center for Human

More information

LOW COST PROTOCOL VERSUS SHORT PROTOCOL FOR CONTROLLED OVARIAN STIMULATION IN ICSI TRIALS

LOW COST PROTOCOL VERSUS SHORT PROTOCOL FOR CONTROLLED OVARIAN STIMULATION IN ICSI TRIALS LOW COST PROTOCOL VERSUS SHORT PROTOCOL FOR CONTROLLED OVARIAN STIMULATION IN ICSI TRIALS Salem H. H. '; Nassar A. M.,&l ; Askalany N. A. ', Kassem K. 1&4 Department of Obstetrics and Gynecology Al Azhar

More information

Effects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment

Effects of functional ovarian cysts detected on the 7th day of gonadotropin-releasing hormone analog administration on the outcome of IVF treatment FERTILITY AND STERILITY VOL. 74, NO. 5, NOVEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effects of functional

More information

Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome

Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome FERTILITY AND STERILITY Copyright e 1993 The American Fertility Society Vol. 59, No.3, March 1993 Printed on acid-free paper in U.S.A. Gonadotropin-releasing hormone agonist reduces the miscarriage rate

More information

Vanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.

Vanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol

More information

Understanding Infertility, Evaluations, and Treatment Options

Understanding Infertility, Evaluations, and Treatment Options Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly

More information

REstradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization

REstradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization REstradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization Does It Improve IVF Outcomes in Poor Responders as Compared to Oral Contraceptive Pill? FTThe Journal of Reproductive

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Lyophilised powder for injection / 75 IU. Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Lyophilised powder for injection / 75 IU. Date of FAR: Core Safety Profile Active substance: Urofollitropin Pharmaceutical form(s)/strength: Lyophilised powder for injection / 75 IU P - RMS: UK/H/PSUR/0059/001 Date of FAR: 04.12.2009 4.2 Posology and method

More information

Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients

Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/25877

More information

Prognostic factors of ovarian response and IVF outcome in patients with deep infiltrating endometriosis Claire GAUCHE-CAZALIS, Chadi YAZBECK

Prognostic factors of ovarian response and IVF outcome in patients with deep infiltrating endometriosis Claire GAUCHE-CAZALIS, Chadi YAZBECK Prognostic factors of ovarian response and IVF outcome in patients with deep infiltrating endometriosis Claire GAUCHE-CAZALIS, Chadi YAZBECK Obstetrics Gynecology and Reproductive Medicine Department Bichat

More information

Is it the seed or the soil? Arthur Leader, MD, FRCSC

Is it the seed or the soil? Arthur Leader, MD, FRCSC The Physiological Limits of Ovarian Stimulation Is it the seed or the soil? Arthur Leader, MD, FRCSC Objectives 1. To consider how ovarian stimulation protocols work in IVF 2. To review the key events

More information

Poor & Hyper responders: what is the best approach?

Poor & Hyper responders: what is the best approach? Poor & Hyper responders: what is the best approach? A. La Marca ObGyn Dept University of Modena and Reggio Emilia Italy Center for Reproductive Medicine University Hospital of Modena Italy Criteria used

More information